Mazal Plant Pharmaceuticals Inc. (PINKSHEETS: MZPP) (Frankfurt: M9J) (“Mazal”) announced that based on the approval that it previously received from the FDA for its HDL elevating drug, MAHDL, it is now negotiating with clinical sites to use the company’s common stock as partial payment for the study in order to conserve working capital for other corporate requirements.
